Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Gastrointestinal Oncology

• Publication date

  2015-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.3978/j.issn.2078-6891.2015.041PMID 26487945PMCID PMC4570924
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.

  2016cited by this paper
• PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT).

  2014cited by this paper
• Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.

  2013cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.

  2011cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997influential reference
• Cancer statistics

  1989cited by this paper

• Current Systemic Treatment Options for Advanced Pancreatic Cancer—An Overview Article

  2026influential citation
• Development of HRP-based 3D intercellular exchange assay for high throughput screening.

  2025cites this paper
• Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment

  2024cites this paper
• N6-methyladenosine modification of FZR1 mRNA promotes gemcitabine resistance in pancreatic cancer.

  2023cites this paper
• Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation

  2023cites this paper
• Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021)

  2021cites this paper
• The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective study

  2021cites this paper
• Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis

  2021cites this paper
• Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives

  2021cites this paper
• Pancreatic adenocarcinoma: Beyond first line, where are we?

  2021cites this paper
• Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer

  2020cites this paper
• Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis

  2020cites this paper
• Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)

  2020cites this paper
• Precision Therapy of Pancreatic Cancer: From Bench to Bedside

  2020cites this paper
• Membrane expression and significance of TRAIL death receptors DR4 and DR5 in Pancreatic cancer

  2020cites this paper
• Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure

  2019cites this paper
• ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.

  2019cites this paper
• Palliative chemotherapy in pancreatic cancer-treatment sequences.

  2019cites this paper
• Chemotherapy for pancreatic cancer.

  2019cites this paper
• Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?

  2018cites this paper
• Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma.

  2018cites this paper
• The Many Different Designs of Phase II Trials in Oncology

  2018cites this paper
• Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX.

  2018cites this paper
• Sequence therapy in metastatic pancreatic cancer

  2018cites this paper
• Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study

  2017cites this paper
• Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions

  2017cites this paper
• Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies

  2017cites this paper
• Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.

  2017cites this paper
• Scientific rationale for integrative and personalised strategies for pancreatic ductal adenocarcinoma management

  2017influential citation
• Pancreatic cancer: New hopes after first line treatment

  2016cites this paper